Regeneron: EYLEA HD Growth Supports Franchise Stability Thesis

What happened

Regeneron's Q1 2026 EYLEA HD U.S. sales surged 52%, offsetting competitive pressure and suggesting the transition to the higher-dose formulation is gaining traction. The company's broad pipeline, including CEMDISIRAN, provides additional growth optionality beyond the core ophthalmology franchise. However, the DeepValue report warns that EYLEA HD's ability to fully offset legacy EYLEA 2mg erosion is uncertain given biosimilar entry and manufacturing delays for the pre-filled syringe. The Dupixent profit-share remains a critical earnings backstop, but concentration risk (41% of 2025 revenue) leaves Regeneron exposed if the Sanofi collaboration falters. With the stock at $774 and a 17.7x P/E, near-term catalysts like the Q2 2026 PFS decision and HD demand trends will determine whether the franchise stabilization narrative holds.

Implication

Over 12-18 months, Regeneron's base case ($830) hinges on EYLEA HD stabilizing total franchise dollars and Dupixent profit-share growing high-single digits. Failure to secure PFS approval or sustained HD demand weakness could trigger a de-rating to $620. The balance sheet provides downside protection but does not prevent valuation compression if the core thesis weakens.

Thesis delta

The news reinforces the 'POTENTIAL BUY' thesis by showing early HD adoption success, but does not resolve the key uncertainty around the sustainability of that growth as biosimilars expand. The market's repricing to $774 already reflects some optimism, requiring confirmation from upcoming demand data and the PFS decision.